Drug profile · INN
obiltoxaximab
NYXTHRACIS (PREVIOUSLY OBILTOXAXIMAB SFL)
obiltoxaximab (NYXTHRACIS (PREVIOUSLY OBILTOXAXIMAB SFL)) is a protective antigen binding agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — obiltoxaximab
- US status
- approved
- Class
- Antiinfectives for systemic use (J06)
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
obiltoxaximab (NYXTHRACIS (PREVIOUSLY OBILTOXAXIMAB SFL)) is a protective antigen binding agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Protective antigen binding agent
Primary target: Protective antigen
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is obiltoxaximab?
obiltoxaximab (NYXTHRACIS (PREVIOUSLY OBILTOXAXIMAB SFL)) is a protective antigen binding agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for obiltoxaximab?
NYXTHRACIS (PREVIOUSLY OBILTOXAXIMAB SFL) is a marketed brand name for obiltoxaximab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of obiltoxaximab?
obiltoxaximab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.